Clinical Trials
3 trialsNCT07285382 2025-12-16
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT05890287 2023-06-06
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase NA Recruiting
NCT05335473 2023-04-06
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Henan Cancer Hospital
Phase 1/2 Unknown